Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 15, 2014 - Issue 13
Submit an article Journal homepage
941
Views
6
CrossRef citations to date
0
Altmetric
Reviews

Update on the pharmacotherapy for myelodysplastic syndromes

Vu H DuongUniversity of Maryland, Marlene and Stewart Greenebaum Cancer Center, 22 S. Greene St. S9D04B, Baltimore, MD 21201-1595, USA
, MD MS,
Rami S KomrokjiH. Lee Moffitt Cancer Center and Research Institute, Department of Hematologic Malignancies, 12902 Magnolia Drive, Tampa, FL 33612, [email protected]
, MD &
Alan F ListH. Lee Moffitt Cancer Center and Research Institute, Department of Hematologic Malignancies, 12902 Magnolia Drive, Tampa, FL 33612, [email protected]
, MD
Pages 1811-1825 | Published online: 31 Jul 2014

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Limin Li, Xiaoqian Zhang, Hongjuan Yu, Mingwen Zhang, Mengyuan Xu, Jie Liu, Yueyue Fu, Hongbin Meng, Chengfang Lyu, Xiaoxia Li & Jin Zhou. (2018) Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations. OncoTargets and Therapy 11, pages 6863-6870.
Read now

Articles from other publishers (5)

Pedro Blecua, Laura Martinez‐Verbo & Manel Esteller. (2020) The DNA methylation landscape of hematological malignancies: an update. Molecular Oncology 14:8, pages 1616-1639.
Crossref
. (2017) Decitabine in TP53 -Mutated AML . New England Journal of Medicine 376:8, pages 796-798.
Crossref
Semira Sheikh, Mina Bekheet, Heidi Olzscha & Nicholas B. La Thangue. 2016. Drug Discovery in Cancer Epigenetics. Drug Discovery in Cancer Epigenetics 373 406 .
Amir T. Fathi, Seth A. Wander, Rawan Faramand & Ashkan Emadi. (2015) Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia. Seminars in Hematology 52:3, pages 165-171.
Crossref
Ashkan Emadi, Rawan Faramand, Brandon Carter-Cooper, Seda Tolu, Laurie A. Ford, Rena G. Lapidus, Meir Wetzler, Eunice S. Wang, Arash Etemadi & Elizabeth A. Griffiths. (2015) Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia. American Journal of Hematology 90:5, pages E77-E79.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.